Qingluoning^® Atomoxetine Hydrochloride Oral Solution is clinically used for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged six years and older. It is a selective norepinephrine reuptake inhibitor (SNRI) that blocks norepinephrine and dopamine transporters in the brain to raise synaptic norepinephrine levels. This mechanism helps control core symptoms of ADHD and improves attention regulation. Atomoxetine Hydrochloride is a leading non-stimulant therapy recommended in the Chinese Guidelines for the Prevention and Treatment of ADHD (Second Edition) and is also listed as a first-line treatment option in numerous domestic and international clinical guidelines. Qingluoning^® Atomoxetine Hydrochloride Oral Solution was approved for marketing in August 2023. Compared with atomoxetine immediate-release solid oral formulations, the oral solution offers greater convenience in administration, improves patient compliance, and provides irreplaceable advantages such as flexible dose adjustment based on body weight.